AusMedTech 2011 Draft Program - Ausbiotech National Conference
AusMedTech 2011 Draft Program - Ausbiotech National Conference
AusMedTech 2011 Draft Program - Ausbiotech National Conference
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Monday 29 October<br />
9:00am – 5:00pm<br />
AusBiotech presents BioPro Professional Development<br />
BioPro Course: The Secret Sauce of Deal Making<br />
Sponsored by the Government of Victoria<br />
Tuesday 30 October<br />
9:00am – 5:00pm<br />
AusBiotech presents BioPro Professional Development<br />
BioPro Course: The Secret Sauce of Deal Making<br />
BioBasics: Industry Knowledge for the Non-Scientist<br />
BioPro Course: Best Practice Valuation in Biotechnology<br />
1:00pm – 2:30pm<br />
AusBiotech-GSK Student Excellence Awards Judging<br />
Judging Panel:<br />
Glenn Cross, Chief Operating Officer, AusBiotech<br />
Dr Carlo Maccarrone, Associate Director Clinical Research, GlaxoSmithKline, Australia<br />
Dr Simon Tucker, Vice President Research CSO, Biota Holdings Limited<br />
Sponsored by GlaxoSmithKline Australia<br />
1 28/09/2012 <strong>Draft</strong> <strong>Program</strong> - subject to change
Wednesday 31 October<br />
7:00am – 6:00pm<br />
9:00am – 11:00am<br />
1:00pm – 5:30pm<br />
<strong>Conference</strong> Registration<br />
Victorian Government Briefing for International Delegates<br />
Venue: Investment Centre, 55 Collins Street, Melbourne<br />
BioIndustry Exhibition & Business Matching Open<br />
1:00pm – 3:00pm Official Opening of AusBiotech 2012<br />
Plenary Session 1|Commercialisation of Medical Innovation<br />
Dr Richard Barker, Director, Centre for Accelerating Medical Innovations, Oxford University<br />
Plenary Session 2|Current Perspectives on Global Life Science Investment<br />
George Milstein, Managing Director & Co-Head Healthcare Investment, Cowen Investment Bank, USA<br />
Official Presentation of the AusBiotech-GSK Student Excellence Awards 2012<br />
Dr Carlo Maccarrone, Associate Director Clinical Research, GlaxoSmithKline, Australia<br />
Sponsored by GlaxoSmithKline Australia<br />
3:00pm – 3:30pm<br />
Afternoon Tea and Networking with BioIndustry Exhibitors<br />
2 28/09/2012 <strong>Draft</strong> <strong>Program</strong> - subject to change
3:30pm – 5:00pm<br />
Development of Biopharmaceuticals<br />
in Australia<br />
Chair: David Hughes, Chief Executive<br />
Officer, BioPharmaceuticals Australia<br />
(BPA)<br />
Dr Trent Munro, Australian Institute<br />
for Bioengineering and Technology<br />
(AIBN), University of Queensland<br />
Alternative Fuels<br />
Chair: Dr Meera Verma, Proprietor,<br />
Headland Vision<br />
Geoff Bell, Chief Executive Officer &<br />
Chairman, Microbiogen<br />
International Investors Unplugged<br />
Chair: Hershel Berry, Managing Partner, Blueprint<br />
Life Sciences, United States<br />
Panellists:<br />
Lawrence Gozlan, Chief Executive Officer, Scientia<br />
Capital<br />
Dr Adam S. Bristol, Portfolio Manager, Aquilo<br />
Capital, United States<br />
Dr Mike Gerometta, Head of CMC<br />
Development, Circadian Technologies<br />
Ltd.<br />
Marc Goemans, Vice President<br />
Marketing & Sales, DSM Biologics<br />
Dr Len Humphreys, Chief Executive Officer,<br />
Licella Pty Ltd<br />
Further speakers to be confirmed<br />
Caley Castelein M.D.., Managing Director, Kearny<br />
Venture Partners , United States<br />
Cayce Denton, Associate, TPG Biotechnology,<br />
United States<br />
Bosun Hau, Portfolio Manager, MVM Life Science<br />
Partners, United States<br />
Session sponsored by DSM Biologics,<br />
Netherlands<br />
Marc Pentopoulos, Portfolio Manager, Symmetry<br />
Capital, United States<br />
Isai Peimer, Principal, MedImmune Ventures,<br />
United States<br />
3 28/09/2012 <strong>Draft</strong> <strong>Program</strong> - subject to change
6:00pm – 7:30pm<br />
AusBiotech – Victorian Government Official Welcome Reception<br />
Showtime Events Centre – 61 South Wharf Promenade, South Wharf<br />
Janssen Industry Excellence Awards Presented<br />
Sponsored by the Government of Victoria<br />
Thursday 1 November<br />
8:00am – 7:00pm<br />
8:00am – 5:00pm<br />
9:00am – 10:30am<br />
Registration Open<br />
Registration, BioIndustry Exhibition & Business Matching Open<br />
Including Trade Afternoon (3:30pm-5:00pm)<br />
Plenary Session 3|Millis Oration<br />
Introduction: Simon Green, Senior Vice President Global Product Development, CSL<br />
New Medicines – How Do We Get Them & How Do We Pay for Them?<br />
Millis Orator: Dr Alan Robertson, Chief Executive Officer, Pharmaxis<br />
Plenary Session 4| Translating Discovery into Products & Services<br />
Plenary Speaker: Prof Ranjeny Thomas, Founder & Director, Dendright<br />
4 28/09/2012 <strong>Draft</strong> <strong>Program</strong> - subject to change
Plenary Session 5| Presentation title to be confirmed<br />
Plenary speaker: Dr Susan Windham-Bannister, President & Chief Executive Officer, Massachusetts Life Sciences Center (MLSC)<br />
10.30am – 11.00am<br />
11:00am – 12:30pm<br />
Morning Tea and Networking with Exhibitors<br />
Commercialising Stem Cell Therapies<br />
Chair: Prof Martin Pera, Director, Stem<br />
Cells Australia<br />
Dr Michael May, Chief Executive Officer,<br />
Centre for Commercialisation of<br />
Regenerative Medicine, Toronto , Canada<br />
Dr Terry Thomas, Senior VP, Research and<br />
Development, Stemcell Technologies,<br />
Vancouver Canada<br />
Prof Paul Simmions, Executive Vice<br />
President Corporate Research & Product<br />
Development, Mesoblast<br />
Big Pharma- The Road Ahead<br />
Chair: Glenn Cross, Chief Operating Officer,<br />
AusBiotech<br />
Greg Wiederrecht, Vice President and Head of<br />
the External Scientific Affairs, MSD<br />
Mark Fladrich, Managing Director Australia &<br />
New Zealand, AstraZeneca<br />
Maintaining Coexistence in the Australian<br />
Seed and Grain Value Chain<br />
David Hudson, GM & CEO, SGA Solutions Pty<br />
Further speaker details coming soon<br />
Session sponsored by The Agricultural<br />
Biotechnology Council of Australia<br />
Session sponsored by the Canadian Trade<br />
Commission<br />
Kathy Connell, Biotechnology Alliance<br />
Manager, Janssen-Cilag<br />
12:30pm – 1:30pm<br />
12:30pm – 1:30pm<br />
1:30pm – 2:30pm<br />
Lunch and Networking with BioIndustry Exhibitors<br />
AusBiotech AGM<br />
AusBiotech Board Meeting<br />
5 28/09/2012 <strong>Draft</strong> <strong>Program</strong> - subject to change
1:30pm – 3:00pm<br />
Australia Succeeds<br />
Changing Strategies in Tech Transfer<br />
Superannuation - Non-Dilutive Capital – A<br />
Plan for the Future<br />
Chair: Dr Anna Lavelle, Chief Executive<br />
Officer, AusBiotech<br />
Chair: Dr Carrie Hillyard, Chair of UniQuest<br />
Chair: Glenn Cross, Chief Operating Officer,<br />
AusBiotech<br />
Greg Collier, Managing Director, Barwon<br />
Biotechnology Pty Ltd<br />
Dr Tony Radford, DR Associates<br />
Dr David Fuller, Senior Vice President<br />
Clinical Development, INC Research<br />
Dr Kevin Cullen, Chief Executive Officer,<br />
UNSW<br />
David Henderson, Managing Director,<br />
UniQuest<br />
Julian Clark, Head Business Development,<br />
Walter & Eliza Hall Institute of Medical<br />
Research<br />
Andrea Slattery, Chief Executive Officer, Self-<br />
Managed Super Fund Professionals<br />
Association of Australia Ltd (SMSF)<br />
Lawrence Gozlan, Chief Executive Officer,<br />
Scientia Capital<br />
Brigitte Smith, Managing Director, GBS<br />
Venture Partners Pty Ltd<br />
Gordon Nobel, Director Advocacy & Policy<br />
Strategy, Association of Super Funds (ASFA)<br />
3:00pm – 3:30pm<br />
Afternoon Tea & Networking with BioIndustry Exhibitors<br />
6 28/09/2012 <strong>Draft</strong> <strong>Program</strong> - subject to change
3:30pm – 5:00pm<br />
Recent Developments in Australian &<br />
US Patent Law & their Impact on the<br />
Biotechnology Industry<br />
Chair: Dr Jenny Petering, Partner, FB Rice<br />
Funding for Early Stage<br />
Chair: Leigh Farrell, Vice President Business<br />
Development, Biota Holdings Ltd<br />
CEO Leaders Forum: Greatest Challenges<br />
Facing the Sector Over the Next 5 Years<br />
Chair: Mr Jeremy Curnock-Cook, Managing<br />
Director, Octa Phillip<br />
Dr Lisa A. Haile, J.D., Partner, Life Sciences<br />
Practice DLA Piper –United States<br />
Dr Gilbert Mintz, Managing Director, <strong>National</strong><br />
Multiple Sclerosis Society, USA<br />
Dr Jackie Fairley, CEO, Starpharma Holdings<br />
Pty Ltd<br />
Nicholas Tyacke, Partner, Life Sciences<br />
Practice DLA Piper<br />
Dean Moss, General Manager - Life Sciences,<br />
Uniquest Pty Ltd.<br />
Dr Deborah Rathjen, CEO & Managing<br />
Director, Bionomics Ltd<br />
Helen Mutimer, Director of Intellectual<br />
Property- Patents and Licensing, R&D<br />
Division, CSL Limited<br />
Dr Mel Billingsley, President & Chief Executive<br />
Officer, Life Sciences Greenhouse of Central<br />
PA, USA<br />
Dr Peter French, Chief Executive Officer,<br />
Benitec Biopharma<br />
Session sponsored by DLA Piper Australia<br />
Chris Nave, Managing Director, Brandon<br />
Capital<br />
5:00pm-6:00pm<br />
6:00pm – 7:00pm<br />
UKTI Cocktails at Booth in BioIndustry Exhibition Hall<br />
(by Invitation only)<br />
Event Partner Reception<br />
7 28/09/2012 <strong>Draft</strong> <strong>Program</strong> - subject to change
7:00pm – 11:00pm<br />
AusBiotech - CSL Official <strong>Conference</strong> Dinner<br />
Friday 2 November<br />
8:00am – 5:30pm<br />
8:00am – 2:00pm<br />
8:00am – 5:30pm<br />
Australasian Life Sciences & Investment Summit (by invitation only – separate registration required)<br />
BioIndustry Exhibition & Business Matching Open<br />
AusFoodtech<br />
9:00am – 10:30am<br />
Doing Business in India<br />
By 2015 the Indian pharmaceutical market is expected to be worth<br />
$20B with 10% of this coming from novel therapeutics. This session<br />
will provide you with knowledge and experience of doing<br />
biotechnology / pharmaceutical business in India.<br />
Session sponsored by The Government of Victoria<br />
VLSCI Life Sciences Computation<br />
Assoc Prof Andrew Lonie, Head of Life Sciences Computation Centre,<br />
VLSCI, Melbourne, Australia.<br />
Prof Gary Egan, Director of Monash Biomedical Imaging (MB), Monash<br />
University, Clayton, Australia<br />
Dr Michael Kuiper, Molecular Modelling Scientist, VLSCI, Melbourne,<br />
Australia<br />
10:30am – 11:00am<br />
Morning Tea and Networking with BioIndustry Exhibitors<br />
8 28/09/2012 <strong>Draft</strong> <strong>Program</strong> - subject to change
11:00am – 12:30pm<br />
Realising Value: Bridging the Gap<br />
Between Science & Commercial Success<br />
Chair: Dr Colin White, President, Invetech<br />
PART 1: Core Science<br />
Market Access: Risk Sharing (Health<br />
Technology Assessment, Value Based<br />
Pricing) Goes Global- Implications for<br />
Australian Biotech<br />
Managing Risks in Clinical Trials<br />
Chair: George Gilmour, Senior Underwriter<br />
Technology Insurance Specialty<br />
Concept /idea, science and technologies<br />
with commercial potential. Building a<br />
business case and lessons learned<br />
Chair: Robert Salt, Founder & Principal, SALT<br />
Global Consulting LLC<br />
Travis McIntosh, Assistant Vice President, Life<br />
Science Specialist, Asia Pacific Zone, Chubb<br />
Insurance Company of Australia Limited<br />
PART 2: Product Development<br />
David James, Director – Biomedical<br />
Instruments & Devices, Invetech<br />
Gary Phillips, Chief Operating Officer,<br />
Pharmaxis<br />
Lisa Nelson, General Manager & Chief<br />
Executive Officer, Nucleus Network<br />
PART 3: Route-to-market<br />
Leigh Farrell, Vice President Business<br />
Development, Biota Holdings Ltd<br />
Session sponsored by Invetech<br />
Further session details to be confirmed<br />
Dr Michelle Miller, Chief Executive Officer &<br />
Managing Director, Biotron Limited<br />
Session sponsored by Chubb Australia Ltd<br />
12:30pm – 2:00pm<br />
Closing Reception<br />
9 28/09/2012 <strong>Draft</strong> <strong>Program</strong> - subject to change
2:30pm – 4:00pm<br />
Public Forum: Re-seeing the Future – How Technology May Restore Vision Loss<br />
Level 2, Melbourne Convention Centre<br />
Moderator: Sally Cockburn, 3AW Dr Feelgood<br />
Panellists:<br />
• Prof Jonathan Crowston, Head Glaucoma Research Unit & Managing Director, CERA<br />
• Prof Robyn Guymer, Head Macular Research Unit, CERA & Bionic Vision<br />
• Alice Pebay, Head Neuroregeneration Unit, CER<br />
• Megan Munsie – Policy & Outreach Manager and Head of Eduation, Law & Community Awareness Unit, Stem Cells Australia<br />
• Maryanne Diamond, GM International & Stakeholder Relations, Vision Australia<br />
10 28/09/2012 <strong>Draft</strong> <strong>Program</strong> - subject to change
Change language